Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence DOI Open Access
Sandra Maria Barbalho, Karina Torres Pomini,

Enzo Pereira de Lima

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3758 - 3758

Published: Nov. 7, 2024

Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB's effects against cancer, focusing its mechanisms of action, efficacy, and clinical implications. We analyzed data from various studies involving both vitro cell line models vivo animal models. The reviewed indicate that CB effectively reduces viability, induces apoptosis, inhibits proliferation, migration, invasion across multiple cancer lines xenograft Specifically, was found to decrease viability increase apoptosis cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, FOXO1. In further demonstrated significant inhibition tumor growth with minimal toxicity. However, limitations include reliance models, which may not fully represent dynamics, lack long-term safety data. also vary their methodologies accurately encompass all subtypes or predict human responses. Despite these limitations, ability target specific pathways results suggest it could be valuable addition treatment strategies. Our suggests trials validate efficacy humans. Future research should explore combination therapies optimize delivery methods enhance outcomes.

Language: Английский

Complanatoside a disrupts copper homeostasis and induces cuproptosis via directly targeting ATOX1 in prostate cancer DOI

Y. Zhao,

Ruonan Wang, Chaoyu Hu

et al.

Toxicology and Applied Pharmacology, Journal Year: 2025, Volume and Issue: 496, P. 117257 - 117257

Published: Feb. 3, 2025

Language: Английский

Citations

0
The role of TRAF2 in pan-cancer revealed by integrating informatics and experimental validation DOI Creative Commons
Xizheng Wang, Jianfeng Yuan, Chenchen Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 12, 2025

Background Tumor necrosis factor (TNF) receptor associated factor-2 (TRAF2) is an E3 ubiquitin ligase and scaffolding protein that contribute to the progression of various malignant tumors. However, role TRAF2 expression in epigenetic, cancer prognosis, immune responses tumor microenvironment unclear. Methods We used The Human Protein Atlas (HPA) database, TIMER 2.0 TCGA database evaluate human normal tissues. Correlation with mutations epigenetic tumors was evaluated using cBioPortal platform GSCA database. To assess prognostic value TRAF2, we performed Kaplan-Meier plots Cox regression analysis. LinkedOmics for PANTHER Pathways enrichment relationship between checkpoint genes, as well cell infiltration, examined R language. Single-cell sequencing data multiple immunofluorescence staining were observe co-expression on hepatocellular carcinoma cells cells. Furthermore, siRNA-mediated knockdown, explored potential liver biology. Results Our findings indicate frequently mutated significantly overexpressed types cancers, this overexpression linked a poor prognosis. alterations significant across cancers. levels genes tumor-infiltrating cells, suggesting its involvement microenvironment. Of note, analysis revealed correlation T activation, single-cell indicated In vivo results demonstrated closely lymphocytes carcinoma. our vitro experimental studies confirmed loss function inhibits behavior HepG2 Conclusion represents biomarker therapeutic target immunotherapy, particularly patients

Language: Английский

Citations

0
Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence DOI Open Access
Sandra Maria Barbalho, Karina Torres Pomini,

Enzo Pereira de Lima

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3758 - 3758

Published: Nov. 7, 2024

Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB's effects against cancer, focusing its mechanisms of action, efficacy, and clinical implications. We analyzed data from various studies involving both vitro cell line models vivo animal models. The reviewed indicate that CB effectively reduces viability, induces apoptosis, inhibits proliferation, migration, invasion across multiple cancer lines xenograft Specifically, was found to decrease viability increase apoptosis cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, FOXO1. In further demonstrated significant inhibition tumor growth with minimal toxicity. However, limitations include reliance models, which may not fully represent dynamics, lack long-term safety data. also vary their methodologies accurately encompass all subtypes or predict human responses. Despite these limitations, ability target specific pathways results suggest it could be valuable addition treatment strategies. Our suggests trials validate efficacy humans. Future research should explore combination therapies optimize delivery methods enhance outcomes.

Language: Английский

Citations

3